Lhermitte-Duclos disease: Difference between revisions
| Line 23: | Line 23: | ||
== Historical Perspective == | == Historical Perspective == | ||
* '''Lhermitte-Duclos disease (LDD)''' was first discovered by Lhermitte and Duclos, in 1920. | |||
==Epidemiology== | ==Epidemiology== | ||
Revision as of 13:40, 16 April 2019
| Lhermitte-Duclos disease | |
 | |
|---|---|
| OMIM | 158350 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Dysplastic cerebellar gangliocytoma
Overview
Lhermitte-Duclos disease (LDD) is also called as dysplastic gangliocytoma of the cerebellum. Lhermitte-Duclos disease (LDD) is a very rare disease. Lhermitte-Duclos disease (LDD) follows an autosomal dominant pattern of inheritance. Lhermitte-Duclos disease (LDD) is a rare entity that may occur in the association of Cowden's syndrome (CS). In The United States of America in order to categorise a condition is a rare disease it should affect fewer than 200,000 people. Rare diseases also called as orphan diseases. Orphan Drug Act was passed on 1983 by congress for the rare diseases. Today an average of 25-30 million americans have been reported with rare diseases. The number of people with individual rare disease may be less but overall the number of people with rare diseases are large in number.
Historical Perspective
- Lhermitte-Duclos disease (LDD) was first discovered by Lhermitte and Duclos, in 1920.